CONMED CEO granted RSUs and stock options
Rhea-AI Filing Summary
Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp President & CEO Pat Beyer received new equity awards, increasing her direct holdings through compensation grants rather than open‑market trades. On March 2, 2026, she was granted 28,800 RSUs, each representing a right to one CONMED common share, and 68,258 stock options.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% the second year, and 34% the third year under CONMED’s 2025 Long-Term Incentive Plan. The stock options were also granted under the 2025 plan and generally vest in equal 25% installments over four years, beginning one year after the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Beyer Pat
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | RSUs (Restricted Stock Units) | 28,800 | $0.00 | $0.00 |
| Grant/Award | Options To Purchase Common Stock | 68,258 | $0.00 | $0.00 |
Holdings After Transaction:
RSUs (Restricted Stock Units) — 28,800 shares (Direct);
Options To Purchase Common Stock — 68,258 shares (Direct)
Footnotes (2)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.
- F2. The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.
FAQ
What insider transactions did CONMED (CNMD) report for Pat Beyer?
CONMED reported that President & CEO Pat Beyer received equity compensation grants, not market trades. She was awarded 28,800 restricted stock units and 68,258 stock options on March 2, 2026, under the company’s 2025 Long-Term Incentive Plan, increasing her direct equity-based interests.
How many RSUs did CONMED (CNMD) grant to CEO Pat Beyer?
Pat Beyer received 28,800 restricted stock units from CONMED. Each RSU represents a contingent right to one share of CONMED common stock. These RSUs were granted under the 2025 Long-Term Incentive Plan and are designed to vest over a multi-year period tied to continued service.
What is the vesting schedule for Pat Beyer’s CONMED (CNMD) RSUs?
The RSUs granted to Pat Beyer generally vest over three years. About 33% vest one year after the grant date, another 33% in the second year, and the remaining 34% in the third year, subject to the terms of CONMED’s 2025 Long-Term Incentive Plan.
How many stock options did CONMED (CNMD) grant to Pat Beyer and how do they vest?
CONMED granted Pat Beyer 68,258 stock options. These options were issued under the 2025 Long-Term Incentive Plan and generally vest in four equal annual installments of 25% each, starting one year after the grant date, encouraging longer-term alignment with shareholders.
Were Pat Beyer’s CONMED (CNMD) equity awards open-market purchases or compensation grants?
Pat Beyer’s reported equity awards were compensation grants, not open-market purchases. The Form 4 shows RSUs and stock options with a transaction code “A” for grant or award acquisition, both issued at a stated price of $0.00 per unit under CONMED’s 2025 plan.
Does Pat Beyer hold CONMED (CNMD) RSUs and options directly or indirectly?
The filing indicates Pat Beyer holds the reported RSUs and stock options directly. The ownership type is marked as direct, with no footnotes describing any trust, partnership, or other entity, meaning the awards are attributed personally to the President & CEO.
AI-generated analysis. How Rhea-AI works. Not financial advice.
